<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04933565</url>
  </required_header>
  <id_info>
    <org_study_id>ORG129-CT01</org_study_id>
    <nct_id>NCT04933565</nct_id>
  </id_info>
  <brief_title>First in Human Study of ORG-129 in Healthy Volunteers</brief_title>
  <official_title>A Study to Assess the Safety, Tolerability and Pharmacokinetics After Single and Multiple Ascending Oral Doses of ORG-129 in Healthy Young Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Origo Biopharma</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Origo Biopharma</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The current study is performed to characterize the safety, tolerability and pharmacokinetics&#xD;
      of ORG-129 after oral intake in healthy male and female volunteers after single ascending and&#xD;
      multiple ascending doses.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 1, 2021</start_date>
  <completion_date type="Anticipated">March 2022</completion_date>
  <primary_completion_date type="Anticipated">February 2022</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To assess the safety and tolerability of SAD of ORG-129</measure>
    <time_frame>day 1 through day 8</time_frame>
    <description>by assessing the number, severity and type of treatment emergent adverse events</description>
  </primary_outcome>
  <primary_outcome>
    <measure>To assess the safety and tolerability of MAD of ORG-129</measure>
    <time_frame>day 1 through day 12</time_frame>
    <description>by assessing the number, severity and type of treatment emergent adverse events</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics of ORG-129 when given as SAD: AUC</measure>
    <time_frame>Day 1 and Day 2</time_frame>
    <description>Area under the plasma concentration-time curve (AUC)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics of ORG-129 when given as SAD: Cmax</measure>
    <time_frame>Day 1 and Day 2</time_frame>
    <description>Maximum observed concentration (Cmax)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics of ORG-129 when given as SAD: Tmax</measure>
    <time_frame>Day 1 and Day 2</time_frame>
    <description>Time to reach maximum observed concentration (Tmax)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics of ORG-129 when given as SAD: CL/F</measure>
    <time_frame>Day 1 and Day 2</time_frame>
    <description>Oral Clearance (CL/F)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics of ORG-129 when given as SAD: Vz/F</measure>
    <time_frame>Day 1 and Day 2</time_frame>
    <description>Terminal Phase Volume of Distribution(Vz/F)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics of ORG-129 when given as SAD: Kel</measure>
    <time_frame>Day 1 and Day 2</time_frame>
    <description>Elimination Rate (Kel)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics of ORG-129 when given as SAD: t 1/2</measure>
    <time_frame>Day 1 and Day 2</time_frame>
    <description>Elimination Halflife (t 1/2)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics of ORG-129 when given as MAD: AUC</measure>
    <time_frame>Day 1 and Day 5</time_frame>
    <description>Area under the plasma concentration-time curve (AUC)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics of ORG-129 when given as MAD: Cmax</measure>
    <time_frame>Day 1 and Day 5</time_frame>
    <description>Maximum observed concentration (Cmax)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics of ORG-129 when given as MAD: Tmax</measure>
    <time_frame>Day 1 and Day 5</time_frame>
    <description>Time to reach maximum observed concentration (Tmax)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics of ORG-129 when given as MAD: CL/F</measure>
    <time_frame>Day 1 and Day 5</time_frame>
    <description>Oral Clearance (CL/F)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics of ORG-129 when given as MAD: Vz/F</measure>
    <time_frame>Day 1 and Day 5</time_frame>
    <description>Terminal Phase Volume of Distribution(Vz/F)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics of ORG-129 when given as MAD: Kel</measure>
    <time_frame>Day 1 and Day 5</time_frame>
    <description>Elimination Rate (Kel)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics of ORG-129 when given as MAD: t 1/2</measure>
    <time_frame>Day 1 and Day 5</time_frame>
    <description>Elimination Halflife (t 1/2)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics of ORG-129 when given as MAD: Css</measure>
    <time_frame>Day 5</time_frame>
    <description>concentration at steady state (Css)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK of ORG-129 when given as MAD: C trough [ Time Frame: Day 2, 5 ]</measure>
    <time_frame>Day 2 and Day 5</time_frame>
    <description>C trough</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">56</enrollment>
  <condition>Healthy Volunteers</condition>
  <arm_group>
    <arm_group_label>ORG-129</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single ascending dose, 4 cohorts, followed by multiple ascending dose, 3 cohorts</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Single ascending dose, 4 cohorts, followed by multiple ascending dose, 3 cohorts</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ORG-129</intervention_name>
    <description>ORG-129 oral capsules</description>
    <arm_group_label>ORG-129</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo oral capsules</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        To be included in the Single Dose Study, subjects should meet all the following criteria at&#xD;
        the screening visit:&#xD;
&#xD;
          1. Healthy male subjects, 18-45 years (inclusive) of age at the time of enrolment.&#xD;
&#xD;
          2. Body weight within normal range (Quetelet's index between 19 and 27) expressed as&#xD;
             weight (kg) / height (m2).&#xD;
&#xD;
          3. Normal clinical records and physical examination.&#xD;
&#xD;
          4. Laboratory tests (hematology and biochemistry) within the range of normal values,&#xD;
             according to the Biochemistry laboratory reference values of the 'Hospital de la Santa&#xD;
             Creu i Sant Pau'. Variations may be admitted according to the clinical criteria of the&#xD;
             CIM-Sant Pau.&#xD;
&#xD;
          5. Clinically acceptable temperature, blood pressure and pulse rate in supine and&#xD;
             standing position (SBP between 100-140 mm Hg/ DBP between 50-90 mm Hg / HR between 50-&#xD;
             100 bpm). Blood pressure and pulse will be measured after a minimum of 3 minutes of&#xD;
             resting.&#xD;
&#xD;
          6. Males should agree to abstain from sexual intercourse with a female partner or agree&#xD;
             to use a condom with spermicide, in addition to having their female partner using some&#xD;
             contraceptive measures as oral contraceptive drugs, intrauterine hormonal&#xD;
             contraception, or cervical caps until 28 days post-administration.&#xD;
&#xD;
          7. To be able to understand the nature of the study and comply with all their&#xD;
             requirements.&#xD;
&#xD;
          8. Free acceptance to participate in the study should be stated in an informed consent&#xD;
             document signed by the volunteer which must be approved by the CREC.&#xD;
&#xD;
        For the Multiple Dose Study, subjects should meet all the following inclusion criteria at&#xD;
        screening visit:&#xD;
&#xD;
          1. Healthy male/female subjects, 18-45 years (inclusive) of age at the time of enrolment.&#xD;
&#xD;
          2. Body weight within normal range (Quetelet's index between 19 and 27) expressed as&#xD;
             weight (kg) / height (m2).&#xD;
&#xD;
          3. Normal clinical records and physical examination at screening and baseline.&#xD;
&#xD;
          4. Laboratory tests (hematology, biochemistry and urianalysis) within the range of normal&#xD;
             values, according to the laboratory reference values of the 'Hospital de la Santa Creu&#xD;
             i Sant Pau'. Variations may be admitted according to the clinical criteria of the&#xD;
             CIM-Sant Pau.&#xD;
&#xD;
          5. Clinically acceptable temperature, blood pressure and pulse rate in supine and&#xD;
             standing position (SBP between 100-140 mm Hg/ DBP between 50-90 mm Hg / HR between 50-&#xD;
             100 bpm). Blood pressure and pulse will be measured after a minimum of 3 minutes of&#xD;
             resting.&#xD;
&#xD;
          6. Males should agree to abstain from sexual intercourse with a female partner or agree&#xD;
             to use a condom with spermicide, in addition to having their female partner using some&#xD;
             contraceptive measures as oral contraceptive drugs, intrauterine hormonal&#xD;
             contraception, or cervical caps until 28 days post-administration.&#xD;
&#xD;
          7. Females must be of non-childbearing potential (i.e., surgically sterile) or have to&#xD;
             use contraceptive measures (non-hormonal) such as condom, diaphragm or cervical/vault&#xD;
             cap with spermicide until 28 days post-administration.&#xD;
&#xD;
          8. To be able to understand the nature of the study and comply with all their&#xD;
             requirements.&#xD;
&#xD;
          9. Free acceptance to participate in the study by obtains signed informed consent form&#xD;
             approved by the CREC.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        For the single dose study and multiple dose study meeting any of the following criteria at&#xD;
        screening visit will be excluded from entry into the study:&#xD;
&#xD;
          1. History of alcohol dependence or drug abuse in the last 5 years or daily consumption&#xD;
             of alcohol &gt; 40 gr/day for men and &gt;24 for women (in MAD).&#xD;
&#xD;
          2. Heavy consumer of stimulating beverages (&gt;5 coffees, teas, chocolate or cola drinks&#xD;
             per day) and grape juice.&#xD;
&#xD;
          3. Background of idiosyncrasy, food intolerance, hypersensitivity or adverse reactions to&#xD;
             any drug or galenical form.&#xD;
&#xD;
          4. Presence or history of allergies requiring acute or chronic treatment (except seasonal&#xD;
             allergic rhinitis).&#xD;
&#xD;
          5. Intake of any medication within 2 weeks prior taking the study treatment (except for&#xD;
             use of paracetamol in short-term symptomatic treatments), including over-the-counter&#xD;
             products (including natural food supplements, vitamins and medicinal plants products),&#xD;
             or any enzymatic inductor or inhibitor within 3 months before the drug administration.&#xD;
&#xD;
          6. Positive serology for hepatitis B, C or HIV.&#xD;
&#xD;
          7. Background or clinically significant evidence of cardiovascular, respiratory, renal,&#xD;
             hepatic, endocrine, gastrointestinal, hematological, neurological disease or other&#xD;
             chronic diseases.&#xD;
&#xD;
          8. History of psychiatric diseases or epileptic seizures.&#xD;
&#xD;
          9. 12 lead ECG obtained at screening with PR ≥ 220 msec, QRS ≥120 msec and QTc ≥ 440&#xD;
             msec, bradycardia (&lt;50 bpm) or clinically significant minor ST wave changes or any&#xD;
             other abnormal changes on the screening ECG that would interfere with measurement of&#xD;
             the QT interval.&#xD;
&#xD;
         10. Having undergone major surgery during the previous 6 months.&#xD;
&#xD;
         11. Smokers (refrained from any tobacco usage, including smokeless tobacco, nicotine&#xD;
             patches, etc.) from 6 months prior to drug administration.&#xD;
&#xD;
         12. Participation in other clinical trials during the previous 90 days (last drug to first&#xD;
             drug administration period) in which an investigational drug or a commercially&#xD;
             available drug was tested.&#xD;
&#xD;
         13. Donation of blood during the 4 weeks preceding the drug administration.&#xD;
&#xD;
         14. Severe or moderate acute illness 4 weeks before drug administration.&#xD;
&#xD;
         15. Clinically significant infections within 3 months or any infection within 28 days of&#xD;
             screening.&#xD;
&#xD;
         16. History or recurrent disseminated herpes simplex or herpes zoster.&#xD;
&#xD;
         17. Personal or family history of hereditary immunodeficiency&#xD;
&#xD;
         18. Clinically significant abnormal laboratory values (as determined by the PI) at the&#xD;
             screening evaluation.&#xD;
&#xD;
         19. Existence of any surgical or medical condition which might interfere with the&#xD;
             absorption, distribution, metabolism or excretion of the drug, i.e. impaired renal or&#xD;
             hepatic function, diabetes mellitus, cardiovascular abnormalities, chronic symptoms of&#xD;
             pronounced constipation or diarrhea or conditions associated with total or partial&#xD;
             obstruction of the urinary tract&#xD;
&#xD;
         20. Positive results of the drugs at screening period or the day before starting treatment&#xD;
             period. A minimum list of 6 drugs will be screened for inclusion: Amphetamines,&#xD;
             Cocaine, Ethanol, Opiates, Cannabinoids and Benzodiazepines (positive results may be&#xD;
             repeated at the discretion of the PI).&#xD;
&#xD;
         21. Females with positive results from the pregnancy test or breast-feeding (MAD).&#xD;
&#xD;
         22. Females with hormonal contraceptive therapy.&#xD;
&#xD;
         23. Positive Covid-19 diagnosis prior to hospital admission&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Juan Martinez-Colomer, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Institut de Recerca de l'Hospital de la Santa Creu i de Sant Pau</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Andrea Sáez, PhD</last_name>
    <phone>+34 981814506</phone>
    <email>andrea.saez@origobiopharma.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Institut de Recerca de l'Hospital de la Santa Creu i de Sant Pau</name>
      <address>
        <city>Barcelona</city>
        <state>Catalonia</state>
        <zip>08025</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Juan Martínez-Colomer, MD</last_name>
      <email>JMartinezCo@santpau.cat</email>
    </contact>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>June 18, 2021</study_first_submitted>
  <study_first_submitted_qc>June 18, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">June 21, 2021</study_first_posted>
  <last_update_submitted>June 18, 2021</last_update_submitted>
  <last_update_submitted_qc>June 18, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 21, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

